* Bicycle Therapeutics PLC BCYC.OQ BCYC.O is expected
to show
a rise in quarterly revenue when it reports results on May 3
(estimated).
* The Cambridge Cambridgeshire-based company is expected to
report a 0.6% increase in revenue to $3.882 million from $3.86
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Bicycle
Therapeutics PLC
is for a loss of $1.07 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 0.3%
in the last three months.
* Wall Street's median 12-month price target for Bicycle
Therapeutics PLC is $53.5, above its last closing price
of $19.76.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -1.05 -1.06 -1.01 Beat 4.6
Sep. 30 2022 -0.86 -0.89 -0.96 Missed -8
Jun. 30 2022 -0.89 -0.85 -0.90 Missed -6.1
Mar. 31 2022 -0.70 -0.68 -0.93 Missed -36.4
Dec. -0.67 -0.61 -0.63 Missed -3.1
31 2021
Sep. 30 2021 -0.63 -0.61 -0.59 Beat 3.5
Jun. 30 2021 -0.68 -0.73 -0.74 Missed -1.9
Mar. 31 2021 -0.73 -0.71 -0.73 Missed -3.3
This summary was machine generated May 1 at 18:33 GMT. All
figures in US dollars unless otherwise stated